US FDA Renews and Expands Licenses of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
FDA holds more than 400 Simcyp and Phoenix software licenses across 12 divisions and offices
Certara's Better Drug Discovery and Development Process
The drug discovery and development process is long and expensive with more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation and tech-enabled services.
In 2020, more than 1,650 customers worldwide chose Certara as their trusted partner for our gold-standard biosimulation software and tech-enabled services. As your trusted partner, we support confident decision-making throughout the entire biopharma R&D process to reduce cycle times, lower costs, and improve outcomes for patients.
Additionally, 17 global regulatory agencies have adopted our Phoenix™ PK/PD and/or Simcyp™ PBPK Simulator software platforms, including the US FDA and EMA.
We are proud to say that our customers, who use our biosimulation software and services, have received over 90% of all new drug approvals by the FDA since 2014.
How we help our clients
Latest from Certara
Webinar: Jan 26
Strategic Application of PBPK Modeling for Predicting DDIs & the Effects of Smoking & Organ Impairment
Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award
Family Driven Development of Treatments for Rare Pediatric Neurological Diseases
Organizing Complex Virology Datasets into FDA-Ready Format using SAS Programming
Pinnacle 21 Awarded FDA Contract for 5 Years for Software and Services
Article: Drug Discovery World
The value of scientific intelligence in drug discovery
Application of quantitative systems pharmacology to guide the optimal dosing of COVID-19 vaccines
Case Study: CAR-T
Using Modeling to Demonstrate the Kinetics of Liso-Cel Transgene
Immunogenicity Prediction and Dose Optimization using Clinically-Validated In Silico Modeling & Simulation
Article: BioIT World
New Discovery Data Architecture Needed to Support New Modalities